<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>Journal of Nanobiotechnology - Latest articles</title>
		<link>http://www.jnanobiotechnology.com</link>
		<description>The latest articles from Journal of Nanobiotechnology (ISSN 1477-3155) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.jnanobiotechnology.com/content/6/1/9"/>			    
            
				    <rdf:li rdf:resource="http://www.jnanobiotechnology.com/content/6/1/8"/>			    
            
				    <rdf:li rdf:resource="http://www.jnanobiotechnology.com/content/6/1/7"/>			    
            
				    <rdf:li rdf:resource="http://www.jnanobiotechnology.com/content/6/1/6"/>			    
            
				    <rdf:li rdf:resource="http://www.jnanobiotechnology.com/content/6/1/5"/>			    
            
				    <rdf:li rdf:resource="http://www.jnanobiotechnology.com/content/6/1/4"/>			    
            
				    <rdf:li rdf:resource="http://www.jnanobiotechnology.com/content/6/1/3"/>			    
            
				    <rdf:li rdf:resource="http://www.jnanobiotechnology.com/content/6/1/2"/>			    
            
				    <rdf:li rdf:resource="http://www.jnanobiotechnology.com/content/6/1/1"/>			    
            
				    <rdf:li rdf:resource="http://www.jnanobiotechnology.com/content/5/1/11"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.jnanobiotechnology.com/content/6/1/9">
            
            <title>The margination propensity of spherical particles for vascular targeting in the microcirculation</title>
			<description>The propensity of circulating particles to drift laterally towards the vessel walls (margination) in the microcirculation has been experimentally studied using a parallel plate flow chamber. Fluorescent polystyrene particles, with a relative density to water of just 50 g/cm3 comparable with that of liposomal or polymeric nanoparticles used in drug delivery and bio-imaging, have been used with a diameter spanning over three order of magnitudes from 50 nm up to 10 micron. The number Ens of particles marginating per unit surface have been measured through confocal fluorescent microscopy for a horizontal chamber, and the corresponding total volume Vs of particles has been calculated. Scaling laws have been derived as a function of the particle diameter d. In horizontal capillaries, margination is mainly due to the gravitational force for  articles with d > 200 nm and Vs increases with d^4; whereas for smaller particles Vs increases with d^3. In vertical capillaries, since the particles are heavier than the fluid they would tend to marginate towards the walls in downward flows and towards the center in upward flows, with Vs increasing with d^9/2. However, the margination in vertical capillaries is predicted to be much smaller than in horizontal capillaries. These results suggest that, for particles circulating in an external field of volume forces (gravitation or magnetic), the strategy of using larger particles designed to marginate and adhere firmly to the vascular walls under flow could be more effective than that of using particles sufficiently small (d &lt; 200 nm) to hopefully cross a discontinuous endothelium.</description>
			<link>http://www.jnanobiotechnology.com/content/6/1/9</link>
			
			 	<dc:creator>Francesco Gentile, Antonio Curcio, Ciro Indolfi, Mauro Ferrari and Paolo Decuzzi</dc:creator>
			
			<dc:source>Journal of Nanobiotechnology 2008, 6:9</dc:source>
			<dc:date>2008-08-15</dc:date>
			<dc:identifier>doi:10.1186/1477-3155-6-9</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Nanobiotechnology</prism:publicationName>
					
			
							
					<prism:issn>1477-3155</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>9</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-15</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jnanobiotechnology.com/content/6/1/8">
            
            <title>Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion</title>
			<description>Background:
Celecoxib, a selective cyclo-oxygenase-2 inhibitor has been recommended orally for the treatment of arthritis and osteoarthritis. Long term oral administration of celecoxib produces serious gastrointestinal side effects. It is a highly lipophilic, poorly soluble drug with oral bioavailability of around 40% (Capsule). Therefore the aim of the present investigation was to assess the skin permeation mechanism and bioavailability of celecoxib by transdermally applied nanoemulsion formulation. Optimized oil-in-water nanoemulsion of celecoxib was prepared by the aqueous phase titration method. Skin permeation mechanism of celecoxib from nanoemulsion was evaluated by FTIR spectral analysis, DSC thermogram, activation energy measurement and histopathological examination. The optimized nanoemulsion was subjected to pharmacokinetic (bioavailability) studies on Wistar male rats.
Results:
FTIR spectra and DSC thermogram of skin treated with nanoemulsion indicated that permeation occurred due to the disruption of lipid bilayers by nanoemulsion. The significant decrease in activation energy (2.373 kcal/mol) for celecoxib permeation across rat skin indicated that the stratum corneum lipid bilayers were significantly disrupted (p &lt; 0.05). Photomicrograph of skin sample showed the disruption of lipid bilayers as distinct voids and empty spaces were visible in the epidermal region. The absorption of celecoxib through transdermally applied nanoemulsion and nanoemulsion gel resulted in 3.30 and 2.97 fold increase in bioavailability as compared to oral capsule formulation.
Conclusion:
Results of skin permeation mechanism and pharmacokinetic studies indicated that the nanoemulsions can be successfully used as potential vehicles for enhancement of skin permeation and bioavailability of poorly soluble drugs.</description>
			<link>http://www.jnanobiotechnology.com/content/6/1/8</link>
			
			 	<dc:creator>Faiyaz Shakeel, Sanjula Baboota, Alka Ahuja, Javed Ali and Sheikh Shafiq</dc:creator>
			
			<dc:source>Journal of Nanobiotechnology 2008, 6:8</dc:source>
			<dc:date>2008-07-09</dc:date>
			<dc:identifier>doi:10.1186/1477-3155-6-8</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Nanobiotechnology</prism:publicationName>
					
			
							
					<prism:issn>1477-3155</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>8</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-09</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jnanobiotechnology.com/content/6/1/7">
            
            <title>Blue shift of CdSe/ZnS nanocrystal-labels upon DNA-hybridization</title>
			<description>Luminescence color multiplexing is one of the most intriguing benefits, which might occur by using semiconductor Quantum Dots (QDs) as labels for biomolecules. It was found, that the luminescence of QDs can be quenched, and replaced by a luminescence peak at approximately 460 nm on hybridization with certain regions of Arabidopsis thaliana tissue. This effect is site selective, and it is unclear whether it occurs due to an energy transfer process, or due to quenching and scattering of the excitation light. The article describes methods for phase-transfer of differently coloured, hydrophobically ligated QDs, coupling of DNA strands to the QD's surface, and hybridization of the labelled DNA to different cell types of Arabidopsis thaliana. The reason for the luminescence blue-shift was studied systematically, and narrowed down to the above mentioned causes.</description>
			<link>http://www.jnanobiotechnology.com/content/6/1/7</link>
			
			 	<dc:creator>J&#252;rgen Riegler, Franck Ditengou, Klaus Palme and Thomas Nann</dc:creator>
			
			<dc:source>Journal of Nanobiotechnology 2008, 6:7</dc:source>
			<dc:date>2008-05-19</dc:date>
			<dc:identifier>doi:10.1186/1477-3155-6-7</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Nanobiotechnology</prism:publicationName>
					
			
							
					<prism:issn>1477-3155</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>7</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-19</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jnanobiotechnology.com/content/6/1/6">
            
            <title>Cationic nanoparticles for delivery of amphotericin B: preparation, characterization and activity in vitro</title>
			<description>Background:
Particulate systems are well known to be able to deliver drugs with high efficiency and fewer adverse side effects, possibly by endocytosis of the drug carriers. On the other hand, cationic compounds and assemblies exhibit a general antimicrobial action. In this work, cationic nanoparticles built from drug, cationic lipid and polyelectrolytes are shown to be excellent and active carriers of amphotericin B against C. albicans.
Results:
Assemblies of amphotericin B and cationic lipid at extreme drug to lipid molar ratios were wrapped by polyelectrolytes forming cationic nanoparticles of high colloid stability and fungicidal activity against Candida albicans. Experimental strategy involved dynamic light scattering for particle sizing, zeta-potential analysis, colloid stability, determination of AmB aggregation state by optical spectra and determination of activity against Candida albicans in vitro from cfu countings.
Conclusion:
Novel and effective cationic particles delivered amphotericin B to C. albicans in vitro with optimal efficiency seldom achieved from drug, cationic lipid or cationic polyelectrolyte in separate. The multiple assembly of antibiotic, cationic lipid and cationic polyelctrolyte, consecutively nanostructured in each particle produced a strategical and effective attack against the fungus cells.</description>
			<link>http://www.jnanobiotechnology.com/content/6/1/6</link>
			
			 	<dc:creator>D&#233;bora B Vieira and Ana M Carmona-Ribeiro</dc:creator>
			
			<dc:source>Journal of Nanobiotechnology 2008, 6:6</dc:source>
			<dc:date>2008-05-07</dc:date>
			<dc:identifier>doi:10.1186/1477-3155-6-6</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Nanobiotechnology</prism:publicationName>
					
			
							
					<prism:issn>1477-3155</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>6</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-07</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jnanobiotechnology.com/content/6/1/5">
            
            <title>A high sensitivity assay for the inflammatory marker C-Reactive protein employing acoustic biosensing</title>
			<description>C-Reactive Protein (CRP) is an acute phase reactant routinely used as a biomarker to assess either infection or inflammatory processes such as autoimmune diseases. CRP also has demonstrated utility as a predictive marker of future risk of cardiovascular disease. A new method of immunoassay for the detection of C-Reactive Protein has been developed using Resonant Acoustic Profiling&#8482; (RAP&#8482;) with comparable sensitivity to a high sensitivity CRP ELISA (hsCRP) but with considerable time efficiency (12 minutes turnaround time to result). In one method, standard solutions of CRP (0 to 231 ng/mL) or diluted spiked horse serum sample are injected through two sensor channels of a RAP&#8482; biosensor. One contains a surface with sheep antibody to CRP, the other a control surface containing purified Sheep IgG. At the end of a 5-minute injection the initial rate of change in resonant frequency was proportional to CRP concentration. The initial rates of a second sandwich step of anti-CRP binding were also proportional to the sample CRP concentration and provided a more sensitive method for quantification of CRP. The lower limit of detection for the direct assay and the homogenous sandwich assay were both 20 ng/mL whereas for the direct sandwich assay the lower limit was 3 ng/mL. In a step towards a rapid clinical assay, diluted horse blood spiked with human CRP was passed over one sensor channel whilst a reference standard solution at the borderline cardiovascular risk level was passed over the other. A semi-quantities ratio was thus obtained indicative of sample CRP status. Overall, the present study revealed that CRP concentrations in serum that might be expected in both normal and pathological conditions can be detected in a time-efficient, label-free immunoassay with RAP&#8482; detection technology with determined CRP concentrations in close agreement with those determined using a commercially available high sensitivity ELISA.</description>
			<link>http://www.jnanobiotechnology.com/content/6/1/5</link>
			
			 	<dc:creator>Jeffrey D McBride and Matthew A Cooper</dc:creator>
			
			<dc:source>Journal of Nanobiotechnology 2008, 6:5</dc:source>
			<dc:date>2008-04-29</dc:date>
			<dc:identifier>doi:10.1186/1477-3155-6-5</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Nanobiotechnology</prism:publicationName>
					
			
							
					<prism:issn>1477-3155</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>5</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-29</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jnanobiotechnology.com/content/6/1/4">
            
            <title>Quantification of specific bindings of biomolecules by magnetorelaxometry</title>
			<description>The binding reaction of the biomolecules streptavidin and anti-biotin antibody, both labelled by magnetic nanoparticles (MNP), to biotin coated on agarose beads, was quantified by magnetorelaxometry (MRX). Highly sensitive SQUID-based MRX revealed the immobilization of the MNP caused by the biotin-streptavidin coupling. We found that about 85% of streptavidin-functionalised MNP bound specifically to biotin-agarose beads. On the other hand only 20% of antibiotin-antibody functionalised MNP were specifically bound. Variation of the suspension medium revealed in comparison to phosphate buffer with 0.1% bovine serum albumin a slight change of the binding behaviour in human serum, probably due to the presence of functioning (non heated) serum proteins. Furthermore, in human serum an additional non-specific binding occurs, being independent from the serum protein functionality.The presented homogeneous bead based assay is applicable in simple, uncoated vials and it enables the assessment of the binding kinetics in a volume without liquid flow. The estimated association rate constant for the MNP-labelled streptavidin is by about two orders of magnitude smaller than the value reported for free streptavidin. This is probably due to the relatively large size of the magnetic markers which reduces the diffusion of streptavidin. Furthermore, long time non-exponential kinetics were observed and interpreted as agglutination of the agarose beads.</description>
			<link>http://www.jnanobiotechnology.com/content/6/1/4</link>
			
			 	<dc:creator>Dietmar Eberbeck, Christian Bergemann, Frank Wiekhorst, Uwe Steinhoff and Lutz Trahms</dc:creator>
			
			<dc:source>Journal of Nanobiotechnology 2008, 6:4</dc:source>
			<dc:date>2008-03-11</dc:date>
			<dc:identifier>doi:10.1186/1477-3155-6-4</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Nanobiotechnology</prism:publicationName>
					
			
							
					<prism:issn>1477-3155</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>4</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-03-11</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jnanobiotechnology.com/content/6/1/3">
            
            <title>A micro-fluidic study of whole blood behaviour on PMMA topographical nanostructures</title>
			<description>Background:
Polymers are attractive materials for both biomedical engineering and cardiovascular applications. Although nano-topography has been found to influence cell behaviour, no established method exists to understand and evaluate the effects of nano-topography on polymer-blood interaction.
Results:
We optimized a micro-fluidic set-up to study the interaction of whole blood with nano-structured polymer surfaces under flow conditions. Micro-fluidic chips were coated with polymethylmethacrylate films and structured by polymer demixing. Surface feature size varied from 40 nm to 400 nm and feature height from 5 nm to 50 nm. Whole blood flow rate through the micro-fluidic channels, platelet adhesion and von Willebrand factor and fibrinogen adsorption onto the structured polymer films were investigated. Whole blood flow rate through the micro-fluidic channels was found to decrease with increasing average surface feature size. Adhesion and spreading of platelets from whole blood and von Willebrand factor adsorption from platelet poor plasma were enhanced on the structured surfaces with larger feature, while fibrinogen adsorption followed the opposite trend.
Conclusion:
We investigated whole blood behaviour and plasma protein adsorption on nano-structured polymer materials under flow conditions using a micro-fluidic set-up. We speculate that surface nano-topography of polymer films influences primarily plasma protein adsorption, which results in the control of platelet adhesion and thrombus formation.</description>
			<link>http://www.jnanobiotechnology.com/content/6/1/3</link>
			
			 	<dc:creator>Caterina Minelli, Akemi Kikuta, Nataliya Tsud, Michael D Ball and Akiko Yamamoto</dc:creator>
			
			<dc:source>Journal of Nanobiotechnology 2008, 6:3</dc:source>
			<dc:date>2008-02-19</dc:date>
			<dc:identifier>doi:10.1186/1477-3155-6-3</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Nanobiotechnology</prism:publicationName>
					
			
							
					<prism:issn>1477-3155</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>3</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-02-19</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jnanobiotechnology.com/content/6/1/2">
            
            <title>Intracellular gold nanoparticles enhance non-invasive radiofrequency thermal destruction of human gastrointestinal cancer cells</title>
			<description>Background:
Novel approaches to treat human cancer that are effective with minimal toxicity profiles are needed. We evaluated gold nanoparticles (GNPs) in human hepatocellular and pancreatic cancer cells to determine: 1) absence of intrinsic cytotoxicity of the GNPs and 2) external radiofrequency (RF) field-induced heating of intracellular GNPs to produce thermal destruction of malignant cells. GNPs (5 nm diameter) were added to 2 human cancer cell lines (Panc-1, Hep3B). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and propidium iodide-fluorescence associated cell sorting (PI-FACS) assessed cell proliferation and GNP-related cytotoxicity. Other GNP-treated cells were exposed to a 13.56 MHz RF field for 1, 2, or 5 minutes, and then incubated for 24 hours. PI-FACS measured RF-induced cytotoxicity.
Results:
GNPs had no impact on cellular proliferation by MTT assay. PI-FACS confirmed that GNPs alone produced no cytotoxicity. A GNP dose-dependent RF-induced cytotoxicity was observed. For Hep3B cells treated with a 67 &#956;M/L dose of GNPs, cytotoxicity at 1, 2 and 5 minutes of RF was 99.0%, 98.5%, and 99.8%. For Panc-1 cells treated at the 67 &#956;M/L dose, cytotoxicity at 1, 2, and 5 minutes of RF was 98.5%, 98.7%, and 96.5%. Lower doses of GNPs were associated with significantly lower rates of RF-induced thermal cytotoxicity for each cell line (P &lt; 0.01). Cells not treated with GNPs but treated with RF for identical time-points had less cytotoxicity (Hep3B: 17.6%, 21%, and 75%; Panc-1: 15.3%, 26.4%, and 39.8%, all P &lt; 0.01).
Conclusion:
We demonstrate that GNPs 1) have no intrinsic cytotoxicity or anti-proliferative effects in two human cancer cell lines in vitro and 2) GNPs release heat in a focused external RF field. This RF-induced heat release is lethal to cancer cells bearing intracellular GNPs in vitro.</description>
			<link>http://www.jnanobiotechnology.com/content/6/1/2</link>
			
			 	<dc:creator>Christopher J Gannon, Chitta Ranjan Patra, Resham Bhattacharya, Priyabrata Mukherjee and Steven A Curley</dc:creator>
			
			<dc:source>Journal of Nanobiotechnology 2008, 6:2</dc:source>
			<dc:date>2008-01-30</dc:date>
			<dc:identifier>doi:10.1186/1477-3155-6-2</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Nanobiotechnology</prism:publicationName>
					
			
							
					<prism:issn>1477-3155</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>2</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-01-30</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jnanobiotechnology.com/content/6/1/1">
            
            <title>N-hexanoyl chitosan stabilized magnetic nanoparticles: Implication for cellular labeling and magnetic resonance imaging</title>
			<description>This project involved the synthesis of N-hexanoyl chitosan or simply modified chitosan (MC) stabilized iron oxide nanoparticles (MC-IOPs) and the biological evaluation of MC-IOPs. IOPs containing MC were prepared using conventional methods, and the extent of cell uptake was evaluated using mouse macrophages cell line (RAW cells). MC-IOPs were found to rapidly associate with the RAW cells, and saturation was typically reached within the 24 h of incubation at 37&#176;C. Nearly 8.53 &#177; 0.31 pg iron/cell were bound or internalized at saturation. From these results, we conclude that MC-IOPs effectively deliver into RAW cells in vitro and we also hope MC-IOPs can be used for MRI enhancing agents in biomedical fields.</description>
			<link>http://www.jnanobiotechnology.com/content/6/1/1</link>
			
			 	<dc:creator>Shanta R Bhattarai, Remant B Kc, Sun Y Kim, Manju Sharma, Myung S Khil, Pyoung H Hwang, Gyung H Chung and Hak Y Kim</dc:creator>
			
			<dc:source>Journal of Nanobiotechnology 2008, 6:1</dc:source>
			<dc:date>2008-01-04</dc:date>
			<dc:identifier>doi:10.1186/1477-3155-6-1</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Nanobiotechnology</prism:publicationName>
					
			
							
					<prism:issn>1477-3155</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>1</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-01-04</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jnanobiotechnology.com/content/5/1/11">
            
            <title>Nanobiotechnology today: focus on nanoparticles</title>
			<description>In the recent years the nanobiotechnology field and the Journal of Nanobiotechnology readership have witnessed an increase in interest towards the nanoparticles and their biological effects and applications. These include bottom-up and molecular self-assembly, biological effects of naked nanoparticles and nano-safety, drug encapsulation and nanotherapeutics, and novel nanoparticles for use in microscopy, imaging and diagnostics. This review highlights recent Journal of Nanobiotechnology publications in some of these areas http://www.jnanobiotechnology.com.</description>
			<link>http://www.jnanobiotechnology.com/content/5/1/11</link>
			
			 	<dc:creator>Mikhail Soloviev</dc:creator>
			
			<dc:source>Journal of Nanobiotechnology 2007, 5:11</dc:source>
			<dc:date>2007-12-30</dc:date>
			<dc:identifier>doi:10.1186/1477-3155-5-11</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Nanobiotechnology</prism:publicationName>
					
			
							
					<prism:issn>1477-3155</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>11</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-12-30</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
